Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing study of pertuzumab + trastuzumab + docetaxel as first-line therapy for HER2-positive inoperable or recurrent breast cancer
jRCT1080222272Phase 4Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2013
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pertuzumab, trastuzumab and docetaxel in breast cancer, sponsored by Chugai Pharmaceutical Co., Ltd. Started Oct 2013; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT1080222272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080222272.